The role of 14-3-3 η as a biomarker in rheumatoid arthritis

被引：5

作者：

Abdelhafiz, Dima ^{[1
,2
]}

Kilborn, Sally ^{[1
,2
]}

Bukhari, Marwan ^{[1
,2
]}

机构：

[1] Univ Hosp Morecambe Bay NHS Fdn Trust, Royal Lancaster Infirm, Ashton Rd, Lancaster LA1 4RP, England

[2] Univ Manchester, Univ Hosp Morecambe Bay NHS Fdn Trust, Bailrigg Lane, Lancaster LA1 4YW, England

来源：

RHEUMATOLOGY AND IMMUNOLOGY RESEARCH | 2021年 / 2卷 / 02期

关键词：

biomarkers; rheumatoid arthritis; diagnostic methods; prognosis; treatment; SERUM; 14-3-3-ETA; PROTEIN; CLASSIFICATION; DIAGNOSIS; SEVERITY; CRITERIA; MARKER;

D O I：

10.2478/rir-2021-0012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rheumatoid arthritis (RA) is a chronic multisystem inflammatory disorder with significant morbidity and mortality. Making an early diagnosis and providing appropriate treatment decisions based on clinical and other parameter results in good disease control. Biomarkers, such as C reactive protein (CRP), anti-cyclic citrullinated peptides (anti-CCP), and erythrocyte sedimentation rate (ESR), have been traditionally used. Recently novel biomarkers are described. This article reviews the evidence behind a novel biomarker 14-3-3 eta that has been found to provide additional diagnostic and prognostic information as well as predicting response to treatment. A systematic literature review is presented showing the evidence behind this molecule.

引用

页码：87 / 90

页数：4

共 27 条

[1] Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome [J].

Agelii, M. Leu ;

Andersson, M. L. E. ;

Jones, B. L. ;

Sjowall, C. ;

Kastbom, A. ;

Hafstrom, I ;

Forslind, K. ;

Gjertsson, I .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (01) :1-10

[2]

Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]

[3] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4] The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis - Results from the Norfolk arthritis register [J].

Bukhari, M. ;

Thomson, W. ;

Naseem, H. ;

Bunn, D. ;

Silman, A. ;

Symmons, D. ;

Barton, A. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :2929-2935

[5] Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis - Results from the Norfolk Arthritis Register study, a large inception cohort [J].

Bukhari, M ;

Lunt, M ;

Harrison, BJ ;

Scott, DGI ;

Symmons, DPM ;

Silman, AJ .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :906-912

[6] Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis [J].

Carrier, Nathalie ;

Marotta, Anthony ;

de Brum-Fernandes, Artur J. ;

Liang, Patrick ;

Masetto, Ariel ;

Menard, Henri A. ;

Maksymowych, Walter P. ;

Boire, Gilles .

ARTHRITIS RESEARCH & THERAPY, 2016, 18

[7] Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity [J].

Curtis, Jeffrey R. ;

van der Helm-van Mil, Annette H. ;

Knevel, Rachel ;

Huizinga, Tom W. ;

Haney, Douglas J. ;

Shen, Yijing ;

Ramanujan, Saroja ;

Cavet, Guy ;

Centola, Michael ;

Hesterberg, Lyndal K. ;

Chernoff, David ;

Ford, Kerri ;

Shadick, Nancy A. ;

Hamburger, Max ;

Fleischmann, Roy ;

Keystone, Edward ;

Weinblatt, Michael E. .

ARTHRITIS CARE & RESEARCH, 2012, 64 (12) :1794-1803

[8] Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis [J].

Emery, P. ;

McInnes, I. B. ;

van Vollenhoven, R. ;

Kraan, M. C. .

RHEUMATOLOGY, 2008, 47 (04) :392-398

[9]

Guan SZ, 2019, ANN CLIN LAB SCI, V49, P57

[10] Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab [J].

Hirata, Shintaro ;

Marotta, Anthony ;

Gui, Yuan ;

Hanami, Kentaro ;

Tanaka, Yoshiya .

ARTHRITIS RESEARCH & THERAPY, 2015, 17

← 1 2 3 →